Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7577727 | 0.91 | EGFR (0.44) | EGFRCSNK2A1CSNK2A2CSNK2BCNR2 | |
| SCHEMBL7585664 | 0.87 | EGFR (0.47) | EGFRERBB2BRAFFBP1MAPT | |
| SCHEMBL7578338 | 0.85 | EGFR (0.47) | EGFRCSNK2A1CSNK2A2CSNK2BPRKCQ | |
| SCHEMBL7585269 | 0.84 | EGFR (0.54) | EGFRERBB2BRAFMAPT | |
| SCHEMBL7580720 | 0.83 | EGFR (0.48) | EGFRCSNK2A1CSNK2A2CSNK2BERBB2 | |
| SCHEMBL7577721 | 0.81 | EGFR (0.45) | EGFRERBB2BRAFFBP1MAPT | |
| SCHEMBL7585329 | 0.78 | EGFR (0.56) | EGFRCSNK2A1HPGDBRAF | |
| SCHEMBL7577862 | 0.77 | CSNK2A1 (0.51) | EGFRCSNK2A1CSNK2A2CSNK2BERBB2 | |
| SCHEMBL7584976 | 0.77 | EGFR (0.58) | EGFRERBB2BRAFMAPT | |
| SCHEMBL7577902 | 0.77 | EGFR (0.54) | EGFRERBB2BRAFMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082420-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082420-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | PKD1, REN, CYP11B1 | EGFR 1041/4885CSNK2A1 525/4885CSNK2A2 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.